Literature DB >> 14666700

Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.

V Thorns1, G F Walter, C Thorns.   

Abstract

The members of the matrix metalloproteinase family (MMP) have the ability to degrade macromolecules of the extracellular matrix and are responsible for tumor invasion and infiltration, limiting the effectiveness of the neurosurgical resection of brain tumors. Among the glial brain tumors, astrocytomas and oligodendrogliomas are the most important tumor entities and require a different therapeutic approach. To determine the pattern of MMP expression in astrocytic and oligodendroglial tumors, sections of astrocytic and oligodendroglial differentiated glioblastomas (WHO grade IV), as well as of anaplastic oligodendrogliomas (WHO grade III) and anaplastic gemistocytic astrocytomas (WHO grade III) were immunostained for MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11. MMP-7, MMP-10 and MMP-11 were strongly expressed by neoplastic gemistocytic astrocytes while oligodendrocytic tumor regions showed only a low immunoreaction. In contrast, MMP-2 and MMP-9 mainly immunolabeled vascular structures. These data indicated that MMP-7, MMP-10 and MMP-11 contribute to the worse prognosis of astrocytic tumors when compared to oligodendrogliomas, while MMP-2 and MMP-9 might play an important role in neo-angiogenesis and tumor vascularization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666700

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  28 in total

1.  Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Authors:  Morris D Groves; Vinay K Puduvalli; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Kurt Jaeckle; Vivien Liu; Kenneth R Hess; Kenneth D Aldape; Victor A Levin
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

2.  Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.

Authors:  Neil T Hoa; Lisheng Ge; Kate L Erickson; Carol A Kruse; Andrew N Cornforth; Yurii Kuznetsov; Alex McPherson; Filippo Martini; Martin R Jadus
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo.

Authors:  Jai-Nien Tung; Chung-Po Ko; Shun-Fa Yang; Chun-Wen Cheng; Pei-Ni Chen; Chia-Yu Chang; Chia-Liang Lin; Te-Fang Yang; Yi-Hsien Hsieh; Kun-Chung Chen
Journal:  J Neurooncol       Date:  2016-06-09       Impact factor: 4.130

4.  Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma.

Authors:  Hai-Gang Li; De-Rong Xie; Xi-Ming Shen; Hong-Hao Li; Hong Zeng; Yun-Jie Zeng
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 5.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Authors:  Balveen Kaur; Fatima W Khwaja; Eric A Severson; Shannon L Matheny; Daniel J Brat; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

6.  Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells.

Authors:  Qi Wang; Jun Qian; Junyu Wang; Chun Luo; Juxiang Chen; Guohan Hu; Yicheng Lu
Journal:  J Neurooncol       Date:  2013-01-06       Impact factor: 4.130

7.  Brain endothelial dysfunction in cerebral adrenoleukodystrophy.

Authors:  Patricia L Musolino; Yi Gong; Juliet M T Snyder; Sandra Jimenez; Josephine Lok; Eng H Lo; Ann B Moser; Eric F Grabowski; Matthew P Frosch; Florian S Eichler
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

8.  Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients.

Authors:  Antonio Drago; Barbara Monti; Diana De Ronchi; Alessandro Serretti
Journal:  Neuropsychobiology       Date:  2014-02-27       Impact factor: 2.328

9.  Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

Authors:  Rose Du; Claudia Petritsch; Kan Lu; Patty Liu; Anna Haller; Ruth Ganss; Hanqiu Song; Scott Vandenberg; Gabriele Bergers
Journal:  Neuro Oncol       Date:  2008-03-21       Impact factor: 12.300

Review 10.  Antiangiogenic therapy in brain tumors.

Authors:  Sajani S Lakka; Jasti S Rao
Journal:  Expert Rev Neurother       Date:  2008-10       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.